Genus (GNS)

Sector:

Pharma and Biotech

Index:

FTSE 250

1,736.00p
   
  • Change Today:
      32.00p
  • 52 Week High: 2,774.00
  • 52 Week Low: 1,637.00
  • Currency: UK Pounds
  • Shares Issued: 66.03m
  • Volume: 30,232
  • Market Cap: £1,146.31m
  • RiskGrade: 128

Director dealings: Genus announces new CEO's compensation, AstraZeneca chair spends £0.23m

By Josh White

Date: Tuesday 02 May 2023

LONDON (ShareCast) - (Sharecast News) - Livestock genetics company Genus saw its shares weaken on Tuesday afternoon after it announced the agreed reward arrangements for its incoming CEO, Jorgen Kokke.
Under the shareholder-approved remuneration policy, Kokke would receive a basic annual salary of $825,000, along with a pension contribution worth 6% of his salary.

Additionally, he would receive payments of £4m, mostly in Genus share awards, as compensation for incentives he held at his previous company, Ingredion.

He would also be eligible for an annual bonus of up to 200% of his salary, with one-third of any bonus paid deferred into shares, and a long-term incentive award of 400% of his salary in September, subject to performance targets and a two-year holding period.

At 1301 BST, shares in Genus were down 0.22% at 2,682p.

K3 Business Technology Group, meanwhile, was in the red after Kestrel Partners acquired 76,564 ordinary shares at an average price of £1.10 per share on 21 April.

Kestrel is indirectly holding voting rights over 26.4% of the company's issued share capital.

On 28 April, Kestrel acquired an additional 2,027 shares at an average price of £1.10 apiece, increasing its indirect voting rights to 26.41% of the company's issued share capital.

K3 said non-executive director Oliver Scott is a partner of Kestrel, and holds a beneficial interest in one of Kestrel's clients, which was deemed to have a beneficial interest in Kestrel's entire legal holding in the company.

At 1052 BST, shares in K3 Business Technology Group were down 2.22% at 110p.

Pharmaceuticals giant AstraZeneca was also in focus after its non-executive chair Michel Demaré purchased 2,000 of its ordinary shares on 28 April, at a price of £117.01 per share, for a total value of £234,020.

At 1307 BST, shares in AstraZeneca were down 0.14% at 11,730p.

Finally, ix Net Zero, an investing company focusing on energy transition and sustainability in the built environment, saw its shares slide despite one of its non-executive directors, Patricia McCall, buying 20,000 shares on 28 April.

McCall paid 13p per share, for a total value of £2,600.

Following this purchase, McCall owned 63,139 ordinary shares, representing 0.1% of the company's shares in issue.

At 1231 BST, shares in ix Net Zero were down 10.42% at 16.12p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Genus Market Data

Currency UK Pounds
Share Price 1,736.00p
Change Today 32.00p
% Change 1.88 %
52 Week High 2,774.00
52 Week Low 1,637.00
Volume 30,232
Shares Issued 66.03m
Market Cap £1,146.31m
RiskGrade 128

Genus Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
95.12% below the market average95.12% below the market average95.12% below the market average95.12% below the market average95.12% below the market average
96.08% below the sector average96.08% below the sector average96.08% below the sector average96.08% below the sector average96.08% below the sector average
Price Trend
59.59% below the market average59.59% below the market average59.59% below the market average59.59% below the market average59.59% below the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Income
84.98% below the market average84.98% below the market average84.98% below the market average84.98% below the market average84.98% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
68.65% below the market average68.65% below the market average68.65% below the market average68.65% below the market average68.65% below the market average
66.67% below the sector average66.67% below the sector average66.67% below the sector average66.67% below the sector average66.67% below the sector average

What The Brokers Say

Strong Buy 5
Buy 2
Neutral 0
Sell 0
Strong Sell 0
Total 7
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Genus Dividends

  Latest Previous
  Interim Final
Ex-Div 29-Feb-24 09-Nov-23
Paid 28-Mar-24 08-Dec-23
Amount 10.30p 21.70p

Trades for 26-Apr-2024

Time Volume / Share Price
17:06 600 @ 1,736.00p
16:35 8,131 @ 1,736.00p
16:35 1 @ 1,736.00p
16:35 86 @ 1,736.00p
16:35 42 @ 1,736.00p

Genus Key Personnel

CFO Alison Henriksen
CEO Jorgen Kokke

Top of Page